No open-market selling at Veraxa Biotech AG in the past year, which is unusual. Instead three insiders bought into about $93,000 worth of VRXA.
Baumann Oliver Rolf (Director) made the biggest buy, worth around $75,000. C-suite participation is part of the picture here.
Zooming out by quarter: Last full quarter: net buying by insiders. Insiders bought in 1 of the last 7 full quarters. 26 investment managers listed VRXA in their latest 13F filings (Q2 2026); more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 29, 2026 | Hosseinion Warren | Director | Buy | 6,024 | $1.67 | $10K | SEC |
| Aug 31, 2026 | Baumann Oliver Rolf | Director | Buy | 50,000 | $1.50 | $75K | SEC |
| Aug 31, 2026 | Antz Christoph Rudiger | CEO | Buy | 5,000 | $1.53 | $8K | SEC |
In the last 12 months Veraxa Biotech AG insiders made open-market purchases worth about $93,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in VRXA was filed on 2026-09-29.
26 investment managers reported holding VRXA in SEC Form 13F filings for Q2 2026.
No congressional trades in VRXA were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).